

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

WHAT IS CLAIMED IS:

1. A compound of the formula:



a pharmaceutically acceptable salt or a prodrug thereof,

wherein

R<sup>1</sup> is alkyl or -NR<sup>7</sup>R<sup>8</sup>, where each of R<sup>7</sup> and R<sup>8</sup> is independently hydrogen or alkyl;

R<sup>2</sup> is hydrogen or alkyl;

each of R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> is independently hydrogen, halide, alkyl, -OR<sup>9</sup> (where R<sup>9</sup> is hydrogen, alkyl, a hydroxy protecting group, or cycloalkylalkyl), -SR<sup>10</sup> (where R<sup>10</sup> is hydrogen or alkyl), or -NR<sup>11</sup>R<sup>12</sup> (where each of R<sup>11</sup> and R<sup>12</sup> is independently hydrogen, alkyl, or a nitrogen protecting group), provided R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are not all simultaneously alkyl); or R<sup>3</sup> and R<sup>4</sup> together with atoms to which they are attached to form heterocyclyl, heteroaryl, or cycloalkyl; and R<sup>14</sup> is hydrogen, lower alkyl or -OR<sup>15</sup>, where R<sup>15</sup> is hydrogen, lower alkyl, or a hydroxy protecting group.

2. The compound according to Claim 1, wherein R<sup>14</sup> is hydrogen.

3. The compound according to Claim 2, wherein R<sup>1</sup> is alkyl.

4. The compound according to Claim 3, wherein R<sup>1</sup> is selected from the group consisting of methyl, ethyl, and isopropyl.

5. The compound according to Claim 3, wherein R<sup>2</sup> is hydrogen.

6. The compound according to Claim 5, wherein each of R<sup>7</sup> and R<sup>8</sup> is independently hydrogen or methyl.

1                   7.     The compound according to Claim 6, wherein each of R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and  
2     R<sup>6</sup> is independently hydrogen, halide, alkyl, or -OR<sup>9</sup>, where R<sup>9</sup> is hydrogen, alkyl, a hydroxy  
3     protecting group, or cycloalkylalkyl; or R<sup>3</sup> and R<sup>4</sup> together with atoms to which they are  
4     attached to form heterocyclyl, heteroaryl, or cycloalkyl.

1                   8.     The compound according to Claim 7, wherein at least one of R<sup>3</sup>, R<sup>4</sup>,  
2     R<sup>5</sup>, and R<sup>6</sup> is alkyl, halide, or -OR<sup>9</sup>, where R<sup>9</sup> is as defined in Claim 1.

1                   9.     The compound according to Claim 8, wherein at least one of R<sup>3</sup>, R<sup>4</sup>,  
2     R<sup>5</sup>, and R<sup>6</sup> is bromo, chloro, fluoro, methoxy, ethoxy, methyl, and hydroxy.


1                   10.    The compound according to Claim 9, wherein

- 2                   (a)    R<sup>3</sup> is methoxy, and R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are hydrogen;  
3                   (b)    R<sup>3</sup> is methyl, R<sup>6</sup> is methoxy, and R<sup>4</sup> and R<sup>5</sup> are hydrogen;  
4                   (c)    R<sup>3</sup> is methyl, R<sup>6</sup> is chloro, and R<sup>4</sup> and R<sup>5</sup> are hydrogen;  
5                   (d)    R<sup>3</sup> is chloro, R<sup>4</sup> is methoxy, and R<sup>5</sup> and R<sup>6</sup> are hydrogen;  
6                   (e)    R<sup>3</sup> is methyl, R<sup>4</sup> is chloro, and R<sup>5</sup> and R<sup>6</sup> are hydrogen;  
7                   (f)    R<sup>3</sup> is methyl, R<sup>4</sup> is methoxy, and R<sup>5</sup> and R<sup>6</sup> are hydrogen;  
8                   (g)    R<sup>4</sup> is chloro, and R<sup>3</sup>, R<sup>5</sup> and R<sup>6</sup> are hydrogen;  
9                   (h)    R<sup>4</sup> is methoxy, and R<sup>3</sup>, R<sup>5</sup>, and R<sup>6</sup> are hydrogen.  
10                  (i)    R<sup>3</sup> is methyl, R<sup>6</sup> is bromo, and R<sup>4</sup> and R<sup>5</sup> are hydrogen;  
11                  (j)    R<sup>3</sup> is bromo, R<sup>4</sup> is methoxy, and R<sup>5</sup> and R<sup>6</sup> are hydrogen;  
12                  (k)    R<sup>3</sup> is methyl, R<sup>4</sup> is bromo, and R<sup>5</sup> and R<sup>6</sup> are hydrogen;  
13                  (l)    R<sup>4</sup> is bromo, and R<sup>3</sup>, R<sup>5</sup> and R<sup>6</sup> are hydrogen; or  
14                  (m)    R<sup>3</sup> is ethoxy and R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are hydrogen.


1                   11.    The compound according to Claim 7, wherein R<sup>3</sup> and R<sup>4</sup> together with  
2     atoms to which they are attached to form furanyl, dihydrofuranyl, or pyrrolyl.

1                   12.    The compound according to Claim 11, wherein R<sup>3</sup> and R<sup>4</sup> together  
2     with atoms to which they are attached to form furanyl or dihydrofuranyl.


13. The compound according to Claim 12; wherein said compound is of the formula:



14. A method for producing an imidazolin-2-ylmethyl-substituted aromatic compound of the formula:



said method comprising contacting a nitrile compound of the formula:



with ethylene diamine to produce the imidazolin-2-ylmethyl-substituted aromatic compound, wherein

$R^1$  is alkyl,  $-NR^7R^8$ , where each of  $R^7$  and  $R^8$  is independently hydrogen or alkyl;

$R^2$  is hydrogen or alkyl;

each of  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  is independently hydrogen, halide, alkyl,  $-OR^9$ ,

where  $R^9$  is hydrogen, alkyl, a hydroxy protecting group, or

cycloalkylalkyl,  $-SR^{10}$ , where  $R^{10}$  is hydrogen or alkyl, or  $-NR^{11}R^{12}$ ,

where each of  $R^{11}$  and  $R^{12}$  is independently hydrogen, alkyl, or a


nitrogen protecting group, provided  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  are not all

simultaneously alkyl); or  $R^3$  and  $R^4$  together with atoms to which they


are attached to form heterocyclyl, heteroaryl, or cycloalkyl; and

$R^{14}$  is hydrogen, lower alkyl or  $-OR^{15}$ , where  $R^{15}$  is hydrogen, lower alkyl, or a hydroxy protecting group.

15. A method for producing an imidazolin-2-ylmethyl-substituted aromatic compound of the formula:



said method comprising contacting an ester compound of the formula:



with ethylene diamine in the presence of a trialkylaluminum to produce the imidazolin-2-ylmethyl-substituted aromatic compound,

wherein

$R^1$  is alkyl,  $-NR^7R^8$ , where each of  $R^7$  and  $R^8$  is independently hydrogen or alkyl;

$R^2$  is hydrogen or alkyl;

each of  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  is independently hydrogen, halide, alkyl,  $-OR^9$ , where  $R^9$  is hydrogen, alkyl, a hydroxy protecting group, or cycloalkylalkyl,  $-SR^{10}$ , where  $R^{10}$  is hydrogen or alkyl, or  $-NR^{11}R^{12}$ , where each of  $R^{11}$  and  $R^{12}$  is independently hydrogen, alkyl, or a nitrogen protecting group; or  $R^3$  and  $R^4$  together with atoms to which they are attached to form heterocyclyl, heteroaryl, or cycloalkyl;

$R^{13}$  is alkyl; and

$R^{14}$  is hydrogen, lower alkyl or  $-OR^{15}$ , where  $R^{15}$  is hydrogen, lower alkyl, or a hydroxy protecting group.

16. The method of Claim 15, wherein the trialkylaluminum is trimethylaluminum or triethylaluminum.

17. A composition comprising:

- (a) a therapeutically effective amount of a compound of Claim 1; and
- (b) a pharmaceutically acceptable carrier.

1           18.    A method for treating a disease state selected from the groups  
2 consisting of urge incontinence, stress incontinence, overflow incontinence, functional  
3 incontinence, sexual dysfunction, nasal congestion, and CNS disorders selected from the  
4 group depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and  
5 cognition, eating disorders, obesity, bulimia and anorexia, said method comprising  
6 administering to a patient in need of such treatment a therapeutically effective amount of a  
7 compound of Claim 1.

1           19.    A method for treating a disease state comprising urinary incontinence  
2 by administering to a subject in need of such treatment an effective amount of a Compound  
3 of Claim 1.  
4

1           20.    The method of Claim 19, wherein the disorder is stress incontinence.

1           21.    The method of Claim 19, wherein the disorder is urge incontinence.

1           22.    A method for treating nasal congestion by administering to a mammal  
2 in need of such treatment an effective amount of a Compound of Claim 1.

1           23.    The method of Claim 22, wherein the disorder is nasal congestion.

1           24.    The method of Claim 23, wherein the disorder is sinusitis or otitis.

1           25.    A method for treating sexual dysfunction by administering to a  
2 mammal in need of such treatment an effective amount of a Compound of Claim 1.